Marathon Oil Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of 18.92 billion. The enterprise value is 23.49 billion.
| Market Cap | 18.92B |
| Enterprise Value | 23.49B |
Important Dates
The last earnings date was Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
| Current Share Class | 1.79B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.11% |
| Shares Change (QoQ) | -1.26% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.75B |
Valuation Ratios
The trailing PE ratio is 33.46.
| PE Ratio | 33.46 |
| Forward PE | n/a |
| PS Ratio | 1.40 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 64.07 |
| P/FCF Ratio | 13.58 |
| P/OCF Ratio | 11.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.19, with an EV/FCF ratio of 16.87.
| EV / Earnings | 41.56 |
| EV / Sales | 1.78 |
| EV / EBITDA | 7.19 |
| EV / EBIT | 12.14 |
| EV / FCF | 16.87 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.17 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 1.83 |
| Debt / FCF | 4.43 |
| Interest Coverage | 15.13 |
Financial Efficiency
Return on equity (ROE) is 5.17% and return on invested capital (ROIC) is 7.16%.
| Return on Equity (ROE) | 5.17% |
| Return on Assets (ROA) | 5.10% |
| Return on Invested Capital (ROIC) | 7.16% |
| Return on Capital Employed (ROCE) | 12.96% |
| Revenue Per Employee | 988,130 |
| Profits Per Employee | 41,439 |
| Employee Count | 13,643 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.26 |
Taxes
| Income Tax | -72.14M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.16% in the last 52 weeks. The beta is 0.13, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -3.16% |
| 50-Day Moving Average | 9.75 |
| 200-Day Moving Average | 9.97 |
| Relative Strength Index (RSI) | 75.89 |
| Average Volume (20 Days) | 10,196 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of 13.48 billion and earned 565.35 million in profits. Earnings per share was 0.31.
| Revenue | 13.48B |
| Gross Profit | 11.04B |
| Operating Income | 2.00B |
| Pretax Income | 493.21M |
| Net Income | 565.35M |
| EBITDA | 3.36B |
| EBIT | 2.00B |
| Earnings Per Share (EPS) | 0.31 |
Balance Sheet
The company has 1.49 billion in cash and 6.17 billion in debt, giving a net cash position of -4.67 billion.
| Cash & Cash Equivalents | 1.49B |
| Total Debt | 6.17B |
| Net Cash | -4.67B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 10.27B |
| Book Value Per Share | 5.74 |
| Working Capital | 1.28B |
Cash Flow
In the last 12 months, operating cash flow was 1.64 billion and capital expenditures -248.23 million, giving a free cash flow of 1.39 billion.
| Operating Cash Flow | 1.64B |
| Capital Expenditures | -248.23M |
| Free Cash Flow | 1.39B |
| FCF Per Share | n/a |
Margins
Gross margin is 81.86%, with operating and profit margins of 14.85% and 4.19%.
| Gross Margin | 81.86% |
| Operating Margin | 14.85% |
| Pretax Margin | 3.66% |
| Profit Margin | 4.19% |
| EBITDA Margin | 24.96% |
| EBIT Margin | 14.85% |
| FCF Margin | 10.33% |
Dividends & Yields
This stock pays an annual dividend of 0.51, which amounts to a dividend yield of 4.87%.
| Dividend Per Share | 0.51 |
| Dividend Yield | 4.87% |
| Dividend Growth (YoY) | 4.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 162.41% |
| Buyback Yield | 0.11% |
| Shareholder Yield | 4.98% |
| Earnings Yield | 2.99% |
| FCF Yield | 7.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Astellas Pharma has an Altman Z-Score of 2.15 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.15 |
| Piotroski F-Score | 7 |